Payment overview · 2025
General Payments
$1,945.85
64 reported records · 16 companies
Healthcare provider profile · identity verified
Yiling Huang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ELMHURST, NY · NPI 1316988504
Verified facts
What the public records show
CMS Open Payments records show Yiling Huang, MD received $1,945.85 in general payments during 2025 across 64 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Paxlovid, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 675 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $531.91 | 27.3% | 15 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $260.40 | 13.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.03 | 10.7% | 8 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $157.83 | 8.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.58 | 6.0% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $116.29 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.15 | 5.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.83 | 5.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.02 | 4.0% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $59.30 | 3.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.61 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.32 | 2.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.98 | 2.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.60 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.55 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.45 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,945.85 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $531.91 | 15 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $260.40 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $208.03 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $208.03 | 8 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $157.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $117.58 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $117.58 | 5 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $116.29 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $78.02 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $61.43 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $61.43 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $59.30 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.63 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.63 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $51.61 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $51.61 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $47.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 165 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 278 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 675 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 52 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 101 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
165 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
278 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
675 | 104 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
63 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
101 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1641 | 208 |
| Losartan Potassium | Losartan Potassium | 877 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 850 | 162 |
| Diclofenac Epolamine | Diclofenac Epolamine | 717 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 713 | 152 |
| Raloxifene Hcl | Raloxifene Hcl | 700 | 117 |
| Simvastatin | Simvastatin | 680 | 108 |
| Kerendia | Finerenone | 675 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 587 | 97 |
| Finasteride | Finasteride | 507 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 74 |
| Omeprazole | Omeprazole | 478 | 95 |
| Alendronate Sodium | Alendronate Sodium | 426 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 78 |
| Metformin Hcl | Metformin Hcl | 396 | 80 |
| Gabapentin | Gabapentin | 360 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 291 | 84 |
| Farxiga | Dapagliflozin Propanediol | 278 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 270 | 63 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 251 | 88 |
| Metformin Hcl Er | Metformin Hcl | 245 | 39 |
| Halobetasol Propionate | Halobetasol Propionate | 233 | 81 |
| Azithromycin | Azithromycin | 227 | 154 |
| Pioglitazone Hcl | Pioglitazone Hcl | 224 | 50 |
| Azelastine Hcl | Azelastine Hcl | 211 | 57 |
| Ammonium Lactate | Ammonium Lactate | 202 | 53 |
| Restasis | Cyclosporine | 202 | 27 |
| Celecoxib | Celecoxib | 190 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 170 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 35 |
| Creon | Lipase/Protease/Amylase | 165 | 28 |
| Famotidine | Famotidine | 162 | 32 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 161 | 26 |
| Meloxicam | Meloxicam | 157 | 57 |
| Glimepiride | Glimepiride | 153 | 26 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 146 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 142 | 38 |
| Mometasone Furoate | Mometasone Furoate | 142 | 31 |
| Meclizine Hcl | Meclizine Hcl | 141 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 32 |
| Donepezil Hcl | Donepezil Hcl | 136 | 20 |
| Lisinopril | Lisinopril | 127 | 23 |
| Jardiance | Empagliflozin | 120 | 15 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 120 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 113 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 104 | 14 |
| Hydrocortisone | Hydrocortisone | 102 | 26 |
| Procto-Med Hc | Hydrocortisone | 101 | 26 |
| Rybelsus | Semaglutide | 101 | 13 |
| Januvia | Sitagliptin Phosphate | 100 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 93 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 92 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 36 |
| Allopurinol | Allopurinol | 90 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 30 |
| Nifedipine Er | Nifedipine | 89 | 16 |
| Atenolol | Atenolol | 88 | 17 |
| Furosemide | Furosemide | 84 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 83 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 15 |
| Xarelto | Rivaroxaban | 81 | 16 |
| Folic Acid | Folic Acid | 80 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 78 | 30 |
| Montelukast Sodium | Montelukast Sodium | 78 | 19 |
| Trazodone Hcl | Trazodone Hcl | 74 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 72 | 35 |
| Telmisartan | Telmisartan | 72 | 13 |
| Methylprednisolone | Methylprednisolone | 68 | 59 |
| Propranolol Hcl | Propranolol Hcl | 67 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 64 | suppressed |
| Irbesartan | Irbesartan | 64 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 64 | suppressed |
| Amoxicillin | Amoxicillin | 63 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 49 |
| Clonazepam | Clonazepam | 61 | 18 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 12 |
| Mupirocin | Mupirocin | 55 | 36 |
| Bepotastine Besilate | Bepotastine Besilate | 52 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 51 |
| Colchicine | Colchicine | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Lidocaine | Lidocaine | 50 | suppressed |
| Ozempic | Semaglutide | 49 | 11 |
| Eliquis | Apixaban | 45 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 45 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Loperamide | Loperamide Hcl | 43 | 27 |
| Cephalexin | Cephalexin | 40 | 29 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Naproxen | Naproxen | 26 | 11 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluocinonide | Fluocinonide | 25 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 25 | suppressed |
| Nexium | Esomeprazole Magnesium | 25 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Tacrolimus | Tacrolimus | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Entecavir | Entecavir | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Diazepam | Diazepam | 16 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Repaglinide | Repaglinide | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Erythromycin | Erythromycin Base | 14 | 12 |
| Felodipine Er | Felodipine | 14 | suppressed |
| Lotemax | Loteprednol Etabonate | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,945.85 · 64 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, Assure WCD, CAPVAXIVE, CREON, Cologuard Collection Kit, Coronary Other, ELIQUIS, FARXIGA, FUROSCIX, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error